newsfilter
← Latest News
PR Newswire·

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

  • Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) for potential securities law violations & fiduciary duty breaches by officers & directors.
  • Sionna Therapeutics stock fell 92% on August 10, 2026, closing at $4.51 following disappointing Phase 2a proof-of-concept results for SION-719 in cystic fibrosis.
  • The PreciSION CF trial failed to meet its key activity endpoint of reducing sweat chloride levels when SION-719 was used with Trikafta.
  • Despite ending the second quarter with substantial financial resources, the company plans to take measures to preserve capital while determining the future of its clinical pipeline.
  • Shareholders who incurred losses may contact Robbins LLP via inquiry, email attorney Aaron Dumas, Jr., or call (800) 350-6003 for representation on a contingency fee basis.